Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERESA: Tezepelumab-induced Clinical Remission in Severe Asthma
jRCTs071230026Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tezepelumab in severe asthma and asthma, sponsored by AstraZeneca. Primary endpoint: Clinical remission at 52 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on jRCTs071230026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230026.